Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 14/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895441 | 1.00 | PIK3CD (0.48) | PIK3CDPIK3CBPIK3CGPIK3CACXCR3 | |
| SCHEMBL12659732 | 0.92 | PIK3CD (0.48) | PIK3CDPIK3CBPIK3CGPIK3CACXCR3 | |
| SCHEMBL1888481 | 0.90 | MAPT (0.52) | CXCR3KCNH2HRH3MAPTLMNA | |
| SCHEMBL1888478 | 0.90 | MAPT (0.52) | CXCR3KCNH2HRH3MAPTLMNA | |
| SCHEMBL1894543 | 0.89 | CXCR3 (0.59) | PIK3CDPIK3CBPIK3CGPIK3CACXCR3 | |
| SCHEMBL1894544 | 0.89 | CXCR3 (0.59) | PIK3CDPIK3CBPIK3CGPIK3CACXCR3 | |
| SCHEMBL12672676 | 0.88 | PIK3CD (0.50) | PIK3CDPIK3CBPIK3CGPIK3CACXCR3 | |
| SCHEMBL5578698 | 0.82 | MEN1 (0.52) | KCNH2HRH3MAPTPDE10ALMNA | |
| SCHEMBL12659739 | 0.81 | CXCR3 (0.50) | CXCR3KCNH2HRH3MAPTLMNA | |
| SCHEMBL14178881 | 0.81 | CXCR3 (0.52) | PIK3CDPIK3CBPIK3CGPIK3CACXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939538-B2 | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | AMGEN INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939538-B2 | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | AMGEN INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20060069099-A1 | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | AMGEN SF, LLC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069099-A1 | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | MSR1, TNF, HLA-DRB1 | PIK3CD 4073/4885PIK3CB 3874/4885PIK3CG 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.